Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...

Many researchers believe that Alzheimer’s happens because of harmful proteins building up in the brain, disrupting how brain ...

UW-Madison said reductions in NIH funding will "ultimately harm the livelihoods of real people across Wisconsin and the ...

In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...

For years, scientists have focused on amyloid beta buildup as the main culprit in Alzheimer’s disease, but a new study suggests the real problem might lie in a stalled protein-cutting process in the ...

A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways, particularly those ...

A major trial in frontotemporal dementia patients has found that oxytocin can help improve symptoms of apathy. A new study ...

One million people are thought to be living with dementia in the UK with one in three of these undiagnosed but early action helps with care and treatment ...

Ongoing collaboration between Eisai and Biogen indicates a strong partnership in the development and commercialization of new treatments for Alzheimer's disease. The European Commission has ...